Palvella Therapeutics (PVLA) Price Target Increased by 39.58% to 115.65

Palvella Therapeutics (PVLA) has received a significantly revised average one-year price target of $115.65 per share, a 39.58% increase from the prior estimate and representing a 38.14% upside from its latest closing price. This upward revision is supported by a strong surge in institutional interest, with the number of funds reporting positions more than doubling by 108.86% last quarter and total institutional shares owned increasing by 51.57% to 8,896K. A bullish outlook is further indicated by a 0.12 put/call ratio and notable stake increases from major holders such as Bvf and Suvretta Capital Management.

Analysis

Palvella Therapeutics (PVLA) has received a substantially revised average one-year price target of $115.65 per share, marking a 39.58% increase from the prior $82.85 estimate dated November 7, 2025. This new target implies a significant 38.14% upside from the latest closing price of $83.72, reflecting a strong consensus among analysts whose individual targets range from $50.49 to $210.00. This upward adjustment signals a robust and increasingly positive outlook from the analyst community.

The bullish sentiment is strongly corroborated by a notable surge in institutional interest and ownership. The number of funds reporting positions in PVLA has more than doubled, increasing by 108.86% to 165 owners in the last quarter, while total institutional shares owned rose by 51.57% to 8,896K shares over the past three months. The average portfolio weight dedicated to PVLA also increased by 22.02% to 0.14%, indicating growing conviction among professional investors.

Further reinforcing this positive trend is significant accumulation by major shareholders, with Bvf increasing its stake by 40.02% to 1,161K shares and Suvretta Capital Management raising its holdings by 13.12% to 822K shares. Both firms substantially increased their portfolio allocation to PVLA. Additionally, a low put/call ratio of 0.12 suggests a strong bullish outlook from options traders, implying limited expectations for downside movement.

Key Decisions for Investors

• Investors should evaluate the revised average price target of $115.65, representing a 38.14% upside, as a potential indicator of future stock performance and analyst expectations.
• Given the substantial increase in institutional ownership and portfolio allocation, investors should monitor continued institutional inflows as a key signal of professional conviction in PVLA.
• While the low put/call ratio indicates a bullish options sentiment, investors should consider the wide range of analyst targets ($50.49 to $210.00) and conduct thorough due diligence on the company's fundamentals before making investment decisions.